Recaticimab is named as a drug or biological intervention in 3 clinical trials in our China trial register, none of which are currently recruiting. Lead sponsors include Peking Union Medical College Hospital (2) and Hunan Cancer Hospital (1). Registered phase: Phase 4. Conditions studied include Acute Ischemic Stroke AIS; Intracranial Atherosclerosis ICAS; Atherosclerotic Plaque.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07466251 | PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (ClinicalTrials.gov ↗) Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque |
Phase 4 | Not yet open |
| NCT07605130 | Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factorial, Randomized, Parallel-Group, Multicenter Trial (ClinicalTrials.gov ↗) Intracranial Arteriosclerosis, Cognitive Impairment |
Phase 4 | Not yet open |
| NCT07674368 | Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed (ClinicalTrials.gov ↗) ALK Fusion-positive Non-small Cell Lung Cancer |
Phase 4 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Ischemic Stroke AIS | 1 |
| Intracranial Atherosclerosis ICAS | 1 |
| Atherosclerotic Plaque | 1 |
| Intracranial Arteriosclerosis | 1 |
| Cognitive Impairment | 1 |
| ALK Fusion-positive Non-small Cell Lung Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College Hospital | 2 |
| Hunan Cancer Hospital | 1 |
| Register | Recaticimab trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Recaticimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Recaticimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.